Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

doi:10.1001/jamaophthalmol.2018.2019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

JAMA ophthalmology - 1 Aug 2018

Lorés-Motta Laura, Riaz Moeen, Grunin Michelle, Corominas Jordi, van Asten Freekje, Pauper Marc, Leenders Mathieu, Richardson Andrea J, Muether Philipp, Cree Angela J, Griffiths Helen L, Pham Connie, Belanger Marie-Claude, Meester-Smoor Magda A, Ali Manir, Heid Iris M, Fritsche Lars G, Chakravarthy Usha, Gale Richard, McKibbin Martin, Inglehearn Chris F, Schlingemann Reinier O, Omar Amer, Chen John, Koenekoop Robert K, Fauser Sascha, Guymer Robyn H, Hoyng Carel B, de Jong Eiko K, Lotery Andrew J, Mitchell Paul, den Hollander Anneke I, Baird Paul N, Chowers Itay

Abstract excerpt

Importance: Visual acuity (VA) outcomes differ considerably among patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) drugs. Identification of pharmacogenetic associations may help clinicians understand the mechanisms underlying this variability as well as pave the way for personalized treatment in nAMD. Objective: To identify genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Choroidal Neovascularization

Share to Chromosomes, Human, Pair 10

Share to Intravitreal Injections

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Open in PubMed Open full text

Identifiers

PMID: 29852030
DOI: 10.1001/jamaophthalmol.2018.2019
PMCID: PMC6142943

Genes

CCT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.PMID 29852030Read ↗

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Semantic proximity Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.Semantic proximity Read ↗

Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Association between Vascular Endothelial Growth Factor Polymorphisms and Age-Related Macular Degeneration: An Updated Meta-Analysis.Semantic proximity Read ↗

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.